Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab Combined With Venetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis Patients With Translocation (11;14)
NCT06629818Phase 2Active, not recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Oct 2024
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax in light-chain amyloidosis, sponsored by Peking Union Medical College Hospital. Primary endpoint: Complete response + very good partial response at 3 months. Started Oct 2024; status: active, not recruiting.
02
Drugs
venetoclax
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on NCT06629818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06629818.